Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2005, the company has established itself as a leader in developing innovative treatments for central nervous system disorders, particularly epilepsy and attention deficit hyperactivity disorder (ADHD). With a strong focus on research and development, Supernus has launched several core products that stand out for their efficacy and safety profiles. The company’s commitment to addressing unmet medical needs has positioned it favourably in the market, earning recognition for its contributions to patient care. Supernus continues to expand its operational reach, with significant activities across North America, and remains dedicated to advancing therapeutic options that improve the quality of life for patients.
DitchCarbon Score
How does Supernus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Supernus Pharmaceuticals, Inc.'s score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Supernus Pharmaceuticals, Inc.'s reported carbon emissions
Supernus Pharmaceuticals, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, as indicated by the absence of specific emissions figures. Additionally, there are no documented reduction targets or climate pledges from the company. As a result, Supernus Pharmaceuticals has not established any formal commitments to reduce carbon emissions or engage in climate initiatives, nor does it inherit any emissions data from a parent company. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, making it essential for Supernus Pharmaceuticals to consider establishing measurable targets and commitments to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Supernus Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
